CCR5+ MDSCs are strong inhibitors of CD8+ CTLs [59], and their presence is associated with melanoma progression: patients with melanoma have a significantly increased frequency of circulating CCR5+ MDSCs compared with healthy volunteers [60]. The gene discussed is CCR5; the disease is melanoma.